Reem Waziry1,2, Mohammed Jawad3,4, Rami A Ballout5, Mohammad Al Akel1, Elie A Akl6,7. 1. Faculty of Health Sciences, American University of Beirut, Beirut, Lebanon. 2. Kirby Institute, University of New South Wales, Sydney, NSW, Australia. 3. Department of Primary Care and Public Health, Imperial College London, London, UK. 4. Academic Department of Primary Care and Population Sciences, University of Southampton, Southampton, UK. 5. Faculty of Medicine, American University of Beirut, Beirut, Lebanon. 6. Department of Internal Medicine, American University of Beirut, Beirut, Lebanon. 7. Department of Clinical Epidemiology & Biostatistics, McMaster University, Hamilton, ON, Canada.
Abstract
Background and aims: A systematic review conducted in 2008 found significant associations between waterpipe tobacco smoking and lung cancer, respiratory disease, periodontal disease and low birthweight. Since then, a number of relevant studies have been published. The objective of this study was to update the systematic review on the effects of waterpipe tobacco smoking on health outcomes. Methods: In May 2015 we electronically searched the following databases with no date restrictions: MEDLINE, EMBASE and the ISI Web of Science using a detailed search strategy with no language restrictions. We also screened the references' lists of the included studies. We included cohort, case-control and cross-sectional studies, and excluded case reports, conference abstracts, editorials and reviews. We excluded studies not conducted in humans, assessing physiological outcomes, not distinguishing waterpipe tobacco smoking from other forms of smoking or not reporting association measures. We assessed risk of bias for each included study and conducted meta-analyses for each of the outcomes of interest. Results: We identified 50 eligible studies. We found that waterpipe tobacco smoking was significantly associated with: respiratory diseases [COPD; odds ratio (OR) = 3.18, 95% confidence interval CI = 1.25, 8.08; bronchitis OR = 2.37, 95% CI = 1.49, 3.77; passive waterpipe smoking and wheeze OR) = 1.97, 95% CI = 1.28, 3.04]; oral cancer OR = 4.17, 95% CI = 2.53, 6.89; lung cancer OR = 2.12, 95% CI = 1.32, 3.42; low birthweight (OR = 2.39, 95% CI = 1.32, 4.32); metabolic syndrome (OR 1.63-1.95, 95% CI = 1.25, 2.45); cardiovascular disease (OR = 1.67, 95% CI = 1.25, 2.24); and mental health (OR 1.30-2.4, 95% CI = 1.20, 2.80). Waterpipe tobacco smoking was not significantly associated with: oesophageal cancer (OR = 4.14, 95% CI = 0.93, 18.46); worse quality of life scores [standardized mean difference (SMD) = -0.16, 95% CI = -0.66, 0.34]; gastric carcinoma (OR = 2.16, 95% CI = 0.72, 6.47); bladder cancer (OR = 1.25, 95% CI = 0.99, 1.57); prostate cancer (OR = 7.00, 95% CI = 0.90, 56.90); hepatitis C infection (OR = 0.98, 95%0.80, 1.21); periodontal disease (OR = 3.00, 5.00); gastro-oesophageal reflux disease (OR = 1.25, 95% CI = 1.01, 1.56); nasopharyngeal carcinoma (OR = 0.49, 95% CI = 0.20, 1.23); bladder cancer (OR = 1.25, 95% CI = 0.99, 1.57); infertility (OR = 2.50, 95% CI = 1.00, 6.30); and mortality (OR = 1.15, 95% CI = 0.93, 1.43). Conclusions: There is accumulating evidence about the association of waterpipe tobacco smoking with a growing number of health outcomes.
Background and aims: A systematic review conducted in 2008 found significant associations between waterpipe tobacco smoking and lung cancer, respiratory disease, periodontal disease and low birthweight. Since then, a number of relevant studies have been published. The objective of this study was to update the systematic review on the effects of waterpipe tobacco smoking on health outcomes. Methods: In May 2015 we electronically searched the following databases with no date restrictions: MEDLINE, EMBASE and the ISI Web of Science using a detailed search strategy with no language restrictions. We also screened the references' lists of the included studies. We included cohort, case-control and cross-sectional studies, and excluded case reports, conference abstracts, editorials and reviews. We excluded studies not conducted in humans, assessing physiological outcomes, not distinguishing waterpipe tobacco smoking from other forms of smoking or not reporting association measures. We assessed risk of bias for each included study and conducted meta-analyses for each of the outcomes of interest. Results: We identified 50 eligible studies. We found that waterpipe tobacco smoking was significantly associated with: respiratory diseases [COPD; odds ratio (OR) = 3.18, 95% confidence interval CI = 1.25, 8.08; bronchitis OR = 2.37, 95% CI = 1.49, 3.77; passive waterpipe smoking and wheeze OR) = 1.97, 95% CI = 1.28, 3.04]; oral cancer OR = 4.17, 95% CI = 2.53, 6.89; lung cancer OR = 2.12, 95% CI = 1.32, 3.42; low birthweight (OR = 2.39, 95% CI = 1.32, 4.32); metabolic syndrome (OR 1.63-1.95, 95% CI = 1.25, 2.45); cardiovascular disease (OR = 1.67, 95% CI = 1.25, 2.24); and mental health (OR 1.30-2.4, 95% CI = 1.20, 2.80). Waterpipe tobacco smoking was not significantly associated with: oesophageal cancer (OR = 4.14, 95% CI = 0.93, 18.46); worse quality of life scores [standardized mean difference (SMD) = -0.16, 95% CI = -0.66, 0.34]; gastric carcinoma (OR = 2.16, 95% CI = 0.72, 6.47); bladder cancer (OR = 1.25, 95% CI = 0.99, 1.57); prostate cancer (OR = 7.00, 95% CI = 0.90, 56.90); hepatitis C infection (OR = 0.98, 95%0.80, 1.21); periodontal disease (OR = 3.00, 5.00); gastro-oesophageal reflux disease (OR = 1.25, 95% CI = 1.01, 1.56); nasopharyngeal carcinoma (OR = 0.49, 95% CI = 0.20, 1.23); bladder cancer (OR = 1.25, 95% CI = 0.99, 1.57); infertility (OR = 2.50, 95% CI = 1.00, 6.30); and mortality (OR = 1.15, 95% CI = 0.93, 1.43). Conclusions: There is accumulating evidence about the association of waterpipe tobacco smoking with a growing number of health outcomes.
Authors: Ziyad Ben Taleb; Mayra Vargas; Mohammad Ebrahimi Kalan; Alison Breland; Thomas Eissenberg; David Brown; Wasim Maziak Journal: Tob Control Date: 2019-11-25 Impact factor: 7.552
Authors: Eva Sharma; Maansi Bansal-Travers; Kathryn C Edwards; Michael J Halenar; Kristie A Taylor; Karin A Kasza; Hannah Day; Hoda T Hammad; Gabriella Anic; Jean Limpert; Lisa D Gardner; Nicolette Borek; Heather L Kimmel; Wilson M Compton; Andrew Hyland; Cassandra A Stanton Journal: Tob Control Date: 2020-05 Impact factor: 7.552
Authors: Mohammed Jawad; Andrea Darzi; Tamara Lotfi; Rima Nakkash; Ben Hawkins; Elie A Akl Journal: J Public Health Policy Date: 2017-08 Impact factor: 2.222
Authors: Nada O F Kassem; Noura O Kassem; Sandy Liles; Sheila R Jackson; Dale A Chatfield; Peyton Jacob; Neal L Benowitz; Melbourne F Hovell Journal: Regul Toxicol Pharmacol Date: 2017-07-14 Impact factor: 3.271
Authors: Taghrid Asfar; Ziyad Ben Taleb; Olatokunbo Osibogun; Estefania C Ruano-Herreria; Danielle Sierra; Kenneth D Ward; Ramzi G Salloum; Wasim Maziak Journal: Subst Use Misuse Date: 2018-11-15 Impact factor: 2.164
Authors: Arash Etemadi; Hooman Khademi; Farin Kamangar; Neal D Freedman; Christian C Abnet; Paul Brennan; Reza Malekzadeh Journal: Tob Control Date: 2016-11-21 Impact factor: 7.552